CD4 and non-small cell lung carcinoma: Our results were also in very close agreement by a detailed and complete study carried out by Kagamu et al. These authors used mass cytometry and found that NSCLC patients responding to nivolumab had a significantly higher percentage of CD62Llow CD4 T cells than non-responders at baseline [34].